

Câncer de Tireóide

Adriamicina + Cisplatina

Adriamicina: 60 mg/m² IV D1

Cisplatina: 40 mg/m² IV D1

a cada 21 dias

Ref. (1)

Sorafenibe

Sorafenibe: 400mg VO BID

Ref. (2)

Paclitaxel

Paclitaxel: 120 mg/m² IV durante 96 horas a cada 21 dias

Ref. (3)

1. Shimaoka K, *et al.* A randomized trial of Adriamicina versus Adriamicina plus cisplatin in patients with advanced thyroid carcinoma. *Cancer* 1985;56:2155–2160.
2. Lam ET, Ringel MD, Kloos RT, Prior TW *et al.* Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. *J Clin Oncol.* 2010 May 10;28(14):2323-30.
3. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. *Thyroid.* 2000;10:587-94.